Largest pharmacogenetic clinical trial in cardiology shows potential benefit in individualized approach to anti-platelet therapy

ROCHESTER, Minn. ? Heart patients who undergo percutaneous coronary intervention (PCI) or stent placement? nonsurgical procedures to improve blood flow to the heart ? are typically prescribed anti-platelet therapy to avoid blood clots that can lead to a heart attack or stroke. New research from the international TAILOR-PCI trial, the largest pharmacogenetics clinical trial in [...]
Source: Mayo Clinic Minnesota News - Category: Hospital Management Source Type: news